Literature DB >> 656277

Chronic pulmonary disease and antipyrine disposition.

S N Agnihotri, R A Clark, S Cooper, A O Iyun, G T Tucker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 656277      PMCID： PMC1429263          DOI： 10.1111/j.1365-2125.1978.tb01641.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

3.  Increased clearance of ethanol from the blood of asthmatic patients.

Authors:  E Sotaniemi; R Isoaho; E Huhti; M Huikko; O Koivisto
Journal:  Ann Allergy       Date:  1972-05

4.  Half-life of tolbutamide in patients with chronic respiratory failure.

Authors:  E Sotaniemi; P Arvela; E Huhti; O Koivisto
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

5.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

6.  Role of blood flow in carbon monoxide- and hypoxic hypoxia-induced alterations in hexobarbital metabolism in rats.

Authors:  R A Roth; R J Rubin
Journal:  Drug Metab Dispos       Date:  1976 Sep-Oct       Impact factor: 3.922

7.  The effect of arterial oxygen tension on antipyrine half-time in plasma.

Authors:  J F Cumming
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

8.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808
  10 in total
  4 in total

Review 1.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 2.  Pulmonary disease and drug kinetics.

Authors:  P du Souich; A J McLean; D Lalka; S Erill; M Gibaldi
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 3.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 4.  Hypoxia, arterial pH and theophylline disposition.

Authors:  M Richer; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.